Epilepsy in Children After Pandemic Influenza Vaccination

Siri E. Håberg, MD, PhD,[a] Kari M. Aaberg, MD,[a,b] Pål Surén, MD, PhD,[a,b] Lill Trogstad, MD, PhD,[a] Sara Ghaderi, MSc, PhD,[a] Camilla Stoltenberg, MD, PhD,[a,c] Per Magnus, MD, PhD,[a,d] Inger Johanne Bakken, MSc, PhD[a]

abstract

OBJECTIVES: To determine if pandemic influenza vaccination was associated with an increased risk of epilepsy in children.

METHODS: Information from Norwegian registries from 2006 through 2014 on all children <18 years living in Norway on October 1, 2009 was used in Cox regression models to estimate hazard ratios for incident epilepsy after vaccination. A self-controlled case series analysis was used to estimate incidence rate ratios in defined risk periods after pandemic vaccination.

RESULTS: In Norway, the main period of the influenza A subtype H1N1 pandemic was from October 2009 to December 2009. On October 1, 2009, 1 154 113 children <18 years of age were registered as residents in Norway. Of these, 572 875 (50.7%) were vaccinated against pandemic influenza. From October 2009 through 2014 there were 3628 new cases of epilepsy (incidence rate 6.09 per 10 000 person-years). The risk of epilepsy was not increased after vaccination: hazard ratio: 1.07; 95% confidence interval: 0.94–1.23. Results from the self-controlled case series analysis supported the finding of no association between vaccination and subsequent epilepsy.

CONCLUSIONS: Pandemic influenza vaccination was not associated with increased risk of epilepsy. Concerns about pandemic vaccination causing epilepsy in children seem to be unwarranted.

[a]Norwegian Institute of Public Health, Oslo, Norway; [b]The National Center for Epilepsy, Oslo University Hospital, Oslo, Norway; [c]Department of Global Public Health and Community Care, University of Bergen, Bergen, Norway; and [d]Institute of Health and Society, University of Oslo, Oslo, Norway

Dr Håberg conceptualized and designed the study, was responsible for the data collection and the analytics plan, and drafted the initial manuscript; Dr Bakken contributed to the data collection and the analytics plan, conducted the analyses, and reviewed and revised the manuscript; Drs Trogstad, Magnus, and Stoltenberg contributed to the conceptualization and design of the study, and the interpretation of results, and critically reviewed the manuscript; Drs Ghaderi, Surén, and Aaberg contributed to the interpretation of results, and critically reviewed the manuscript; and all authors approved the final manuscript as submitted.

DOI: https://doi.org/10.1542/peds.2017-0752

Accepted for publication Dec 5, 2017

Address correspondence to Siri E. Håberg, MD, PhD, Norwegian Institute of Public Health, PO Box 4404 Nydalen, 0403 Oslo, Norway. E-mail: siri.haberg@fhi.no

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

POTENTIAL CONFLICTS OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

WHAT'S KNOWN ON THIS SUBJECT: Influenza vaccination has been associated with an increased risk of febrile seizures in children. There is a link between febrile seizures, particularly complex febrile seizures, and an increased risk of later epilepsy.

WHAT THIS STUDY ADDS: Concerns about pandemic vaccination increasing the risk of epilepsy in children seem to be unwarranted.

To cite: Håberg SE, Aaberg KM, Surén P, et al. Epilepsy in Children After Pandemic Influenza Vaccination. *Pediatrics.* 2018;141(3):e20170752

Seizures, including febrile seizures, are the most commonly reported neurologic complication of influenza infection.[1–10] Influenza vaccinations have also been associated with an increased risk of febrile seizures in children.[11–14] We have previously shown that vaccination against pandemic influenza increased the risk of febrile seizures in children, although to a lower degree than influenza infection,[1] and there have been concerns about an association with later epilepsy. There has been increasing focus on the role of infections and immunologic factors, not only in febrile seizures, but also in the etiology of epilepsy.[15–17]

Epilepsy is defined by the occurrence or high risk of recurrent, unprovoked seizures.[18] Childhood epilepsy has many different causes, but in most cases the causal mechanisms are not identified.[19] However, there is a clear link between febrile seizures, particularly complex febrile seizures, and increased risk of later epilepsy.[20–26] The role of influenza infection as a causal trigger of epilepsy is not clear. In one matched case-control study, which included people of all ages, the authors found no increased risk of epilepsy after influenza infection.[27] In other studies, authors have found neurologic complications such as meningitis and encephalitis in relation to influenza infections,[3–6,8,9,28,29] and these complications may in turn increase the risk of later epilepsy.

The role of vaccination as a causal factor or trigger of epilepsy is still unclear.[30–32] In several studies, including a study from Sweden on the Pandemrix vaccine (GlaxoSmithKline, Brentford, United Kingdom), authors found there was no increased risk of epileptic seizures after vaccination.[30,33,34] Other studies conclude that vaccines may trigger seizures in children with underlying susceptibility.[30–32] It has previously been shown that children were at an increased risk of seizures, including febrile seizures, after pandemic influenza vaccination.[1] Increased seizure risk has also been described after administration of other vaccines,[35,36] but the association with later epilepsy is less clear. In some studies of epilepsy onset after vaccination, genetic or structural etiologies were found in most children with onset of epilepsy around the time of vaccination, supporting the view of vaccinations as possible precipitating factors of first seizures in susceptible children, rather than as primary, causal factors.[31,32]

In several studies, authors conclude that pandemic vaccination may influence the risk of other neurologic conditions, such as Guillain-Barré syndrome, encephalopathies, and narcolepsy,[6–9] suggesting there is a potential influence on the brain when the immune system has been triggered by vaccination.[37,38] However, no association with narcolepsy was found in a study of a nonadjuvanted pandemic influenza vaccine used in the United States.[39]

During the 2009 influenza pandemic, Pandemrix, a monovalent AS03-adjuvanted influenza A(H1N1) pmd09 vaccine, was offered free of charge to all citizens in Norway. We investigated the risk of epilepsy after pandemic influenza vaccination in children by linking individual level information from several national health registries that cover the entire Norwegian population.

METHODS

The study was approved by the Regional Committee for Medical and Health Research Ethics, located in southeast Norway.

Data Sources

Norway has a nationwide public health care system in which access to specialist care requires referral from a general practitioner.[40] Hospitals and outpatient clinics are financed through government funding, and health care is free of charge for children up to age 16. Outpatients older than 16 years pay a minor fee, whereas hospitalization is free of charge for all citizens. Norway has several nationwide, mandatory registries and health databases with individual-level data. The unique identification numbers given to all residents at birth or at immigration enables linkage of information. We linked data from the National Registry[41] (census information), the Norwegian Patient Registry[42] (specialist health care data and hospitalizations), the Norwegian Immunization Register[43] (information on pandemic vaccinations), and the national primary care reimbursement system.[44] The Norwegian Patient Registry contains individual-level data from all Norwegian hospitals and outpatient clinics from 2008 onwards, including dates of discharge from the hospital or outpatient visit, and diagnoses reported as *International Classification of Diseases, 10th Revision* codes. Reporting is mandatory and linked to the reimbursement system. Information from primary care was retrieved from the reimbursement system and included dates of consultation and diagnostic codes based on the *International Classification of Primary Care, Second Edition*.

Study Population

In Norway, the main wave of the pandemic influenza period lasted from October 2009 to December 2009.[45] The study population included all children registered in the National registry on October 1, 2009 who were born after January 1, 1991 (age 0–17 years on October 1, 2009) (N = 1 154 113). The National Registry provided information on sex, date of birth, and dates of emigrations and deaths.

Exposure: Pandemic Influenza Vaccination

Dates of vaccination with Pandemrix were obtained from the Norwegian Immunization Register. Reporting of all administered vaccines was mandatory. The vaccination period overlapped with the main period of the pandemic, and 98.4% of vaccines to children were given between October 19, 2009 (the first day with available vaccines), and December 31, 2009.

Outcome: Epilepsy

To reduce the risk of misclassifying prevalent epilepsy as incident, all children with any registration of epilepsy in either primary care (*International Classification of Primary Care, Second Edition* code N88 "epilepsy"), or in specialist care (*International Classification of Diseases, 10th Revision* codes G40 "epilepsy" or G41 "status epilepticus") before October 2009 (the start of the study period) were excluded from the population at risk for incident epilepsy. Information on previously registered epilepsy was available from January 1, 2006, in primary care and from January 1, 2008, in specialist health care. A stricter definition was used to define epilepsy in the study period and required at least 2 records with the codes G40 or G41 in specialist care. This definition has recently been shown to have a positive predictive value for clinical epilepsy of 88%[46] in a Norwegian study based on the same registry data and population as in the current study. For children fulfilling this criterion, and thus were defined as having epilepsy, the first seizure episode was then defined as the date of first registration with either G40, G41, or R56 ("convulsions, not elsewhere classified"). The R56 code was included to identify the first seizure episode because most children do not get the epilepsy diagnosis at first admission with seizures. Children who fulfilled the case criteria for incident epilepsy (at least 2 registrations with G40/G41 during the follow-up period), but with R56 registered before the start of the follow-up period, were reclassified as prevalent cases and excluded from follow-up.

Statistical Analysis

Crude incidence rates were calculated as the number of new cases with epilepsy divided by the sum of person-years at risk, overall and separately for exposed and unexposed time periods. Hazard ratios (HRs) of epilepsy, with associated 95% confidence intervals (CIs), were estimated by using Cox regression analyses with number of days since October 1, 2009, as the time metric. Children were managed until the first episode of epilepsy, until death, emigration, or the end of the study period (December 31, 2014), whichever occurred first. We adjusted for sex and age (on October 1, 2009) in 2 categories (0 to 9 years of age and 10 to 17 years of age). In separate models, we additionally adjusted for the number of specialist health care contacts (outpatient visits and hospitalizations) occurring in the year before the start of the study period (ie, from October 1, 2008 through September 30, 2009) using 3 categories (0, 1–3, and ≥4 contacts). A pandemic vaccination was defined as a time-dependent exposure, and children were considered to be exposed from the day of vaccination. In the Cox regression analyses, incidence rates in exposed time periods were compared with incidence rates in unexposed time periods. We used a risk window of 365 days after vaccination. Analyses were performed for all ages combined and further stratified by below and above 10 years of age.

Additionally, we applied a self-controlled case series (SCCS) analysis to estimate the incidence rate ratio (IRR) of first epileptic episodes in predefined risk periods after influenza vaccination compared with a background period. This method eliminates time-independent confounding because children with epilepsy serve as their own controls.[47,48] For each individual, the observation period was restricted to a period starting 180 days before vaccination or on the day of birth (whichever came last) and ending 180 days after vaccination or on the day of emigration or death (whichever came first). Thus, each individual could contribute with a maximum of 360 observation days. We stratified person-time and events for each individual by the following risk periods: 180 to 15 days pre-exposure, 14 to 0 days pre-exposure, 0 to 6 days postexposure, 7 to 90 days post-exposure, and 91 to 180 days postexposure. The 180 to 15 days pre-exposure and 91 to 180 days postexposure periods were joined together to constitute the background period. IRR estimates were obtained by using conditional Poisson regression.

Testing was 2-sided and $P < .05$ was considered statistically significant. The Stata software package, version 14.1 (StataCorp, College Station, TX) was used for data analysis.

RESULTS

Among the 1 154 113 children below 18 years of age who were registered as residents in Norway on October 1, 2009, 8567 children with prevalent epilepsy were excluded from the study population. This left data for 1 145 546 children eligible for analyses.

From October 2009 to 2014, the total follow-up time was 5 956 513 person-years. There were 3628 new cases of epilepsy, giving an incidence rate of epilepsy of 6.09 per 10 000 person-years. Pandemic influenza vaccines were distributed to 572 875 children (50.7%) (Table 1). The vaccination coverage was higher in children younger than 10 years of age (56.2%)

than in older children (45.2%). There was no indication of an increased risk of epilepsy in children after pandemic vaccination (overall HR in the fully adjusted model, 1.07, 95% CI, 0.94–1.23), as shown in Table 2. Results were similar in analyses without adjustment for previous health care contacts (Table 2).

Results from the SCCS analyses did not show an increased risk after vaccination in any of the predefined risk periods (Fig 1, Table 3).

TABLE 1 Characteristics of All Children Who Were Residents of Norway as of October 1, 2009

	No. Children		Vaccinated	
	No.	%	No.	%
Total	1 139 715	100	577 579	50.7
Age on October 1, 2009				
0–9 y	569 552	50.0	319 824	56.2
10–17 y	570 163	50.0	257 755	45.2
Sex				
Male	584 445	51.3	293 081	50.1
Female	555 270	48.7	284 498	51.2

DISCUSSION

There are few studies in which epilepsy after pandemic vaccination has been investigated; however, in some studies it has been found to increase risk of febrile seizures after vaccinations, including influenza vaccination.[1,11–13] In this nationwide Norwegian registry-based study, we found no increase in risk of epilepsy after vaccination with the adjuvanted pandemic vaccine.

The main strength of the study was the availability of registry data from the entire Norwegian population, which eliminates selection bias. We used independent data sources and linked individual-level data. Independent data collection minimizes differential information bias in reporting. Also, the public health system in Norway aims at providing similar health services to all citizens, and services are free for all children and at low cost for those over 16 years of age. Thus, availability of vaccines and the availability of health care for children with seizures are similar for all socioeconomic groups. The availability of information on the timing of events allowed for detailed assessment of risk windows. Registration of pandemic vaccinations in the national vaccination registry was mandatory and is considered to be nearly complete. Differential misclassification or selection bias based on vaccine status is therefore unlikely.

Nearly all children with chronic diseases are diagnosed and treated within the public health system in Norway, and thus, registered in the databases used in this study. The definition of epilepsy was based on repeated registrations in specialist health services. Diagnoses were not validated, but our definition of incident epilepsy based on specialist care registrations has been shown to have a high positive predictive value for clinical epilepsy.[46] The overall incidence of epilepsy found in this study is in line with the incidence found in a large cohort study of Norwegian children based on the review of medical records and parental interviews,[46] and also similar to incidences in other high-income countries.[49] As in these other studies, we also found the highest incidence of epilepsy among the youngest children.

Children with epilepsy are managed more frequently by health services and could more likely be vaccinated against influenza. This could inflate associations between influenza vaccinations and epilepsy if incident epilepsy was not well-defined. We therefore made additional efforts to improve the validity of our case definition of incident epilepsy. Children with epilepsy in Norway are usually followed-up at least once a year in specialist services.[50] Those who were diagnosed with epilepsy before the pandemic would most likely have been registered in the Norwegian Patient Registry between

TABLE 2 Incidence Rates and HRs of Epilepsy Within 1 Year After Pandemic Vaccination

Age in 2009	Vaccinated	No. Person-y at Risk[a]	No. Cases	Incidence Rate[b]	Crude		Adjusted[c]		Adjusted[d]	
					HR	95% CI	HR	95% CI	HR	95% CI
0–17 y	Yes	571 048.5	432	5.87	1.16	1.02–1.33	1.12	0.98–1.28	1.07	0.94–1.23
	No	5 311 002.1	3116	7.56	1	—	1	—	1	—
0–9 y	Yes	316 716.8	271	8.56	1.09	0.92–1.31	1.09	0.92–1.31	1.05	0.88–1.26
	No	2 620 757.8	1864	7.11	1	—	1	—	1	—
10–17 y	Yes	254 331.7	161	6.33	1.18	0.96–1.46	1.18	0.95–1.46	1.13	0.92–1.40
	No	2 690 244.3	1252	4.65	1	—	1	—	1	—

—, not applicable.

[a] Follow-up time from October 1, 2009, to December 31, 2014, for 1 145 512 residents of Norway born between 1991–2009. Data for 34 children with 0 follow-up time were excluded from the analyses.

[b] Number of new cases per 10 000 person-years at risk.

[c] Adjusted for sex and age-group.

[d] Adjusted for sex, age-group, and overall number of hospitalizations and outpatient visits in the year before the study.



FIGURE 1
Number of days from vaccination to first epileptic episode, in 30 days before and after vaccination.

TABLE 3 IRR of Epilepsy After Pandemic Vaccination Estimated by the SCCS Method

Period	No. Person-d at Risk	No. Events	Incidence Rate per 100 Person-d	IRR (95% CI)
Background period[a]	162 560	471	0.29	1 (ref)
2 wk before vaccination day	8890	26	0.29	1.01 (0.68–1.50)
0–6 d after vaccination	4445	7	0.16	0.54 (0.26–1.15)
7–90 d after vaccination	53 340	131	0.25	0.85 (0.70–1.03)

[a] The 180–15 d pre-exposure and 91–180 d postexposure periods were included in the background period.

January 1, 2008, and October 1, 2009. We also excluded children with any registration of epilepsy in primary health care before the start of the study period. Consequently, the likelihood of bias as a result of misclassification of prevalent cases as incident cases is low.

Another limitation is the lack of detailed information on potential confounding factors, such as underlying conditions that may increase both the likelihood of vaccination and the probability of developing epilepsy. However, SCCS analysis eliminates confounding from factors that do not vary with time and these results supported the results from the Cox analyses.

The biological mechanisms that could explain a connection between inflammatory mechanisms, seizures and epilepsy are not clear,[16] but proinflammatory cytokines have been shown to increase in relation to febrile seizures.[51] Neural inflammation and cytokine release can also be induced by viral infections.[52] Infections, vaccines and fever may trigger seizures, and susceptible individuals may develop epilepsy after febrile seizure episodes.[2,6,8,10,20–24,31,35,53–61] We have previously shown that children were at risk for febrile seizures after pandemic influenza infection, and, to a lower degree, also after pandemic influenza vaccination.[1] Febrile seizures are most often benign, but complex febrile seizures are associated with increased risk of epilepsy.[21–23,61–64] The risk of neurologic conditions, such as Guillain-Barré and narcolepsy, have also been found to be increased after pandemic vaccination.[37,38,65] Concerns about the role of vaccines as cause of neurologic and developmental disorders in children may reduce the willingness to participate in vaccination programs. Low vaccination rates may have consequences for susceptible individuals with higher risk of influenza complications. It is therefore important to perform large population-based studies exploring the risk of neurologic conditions after vaccinations to address such concerns. Our finding of no increased risk of epilepsy after influenza vaccination is reassuring.

CONCLUSIONS

Pandemic influenza vaccination was not associated with an increased risk of epilepsy in children under the age of 18. Concerns about pandemic vaccination causing epilepsy in children seem to be unwarranted.

ABBREVIATIONS

CI: confidence interval
HR: hazard ratio
IRR: incidence rate ratio
SCCS: self-controlled case series

FUNDING: Supported by the Norwegian Research Council grant 201919.

REFERENCES

1. Bakken IJ, Aaberg KM, Ghaderi S, et al. Febrile seizures after 2009 influenza A (H1N1) vaccination and infection: a nationwide registry-based study. *BMC Infect Dis*. 2015;15:506
2. Chiu SS, Tse CY, Lau YL, Peiris M. Influenza A infection is an important cause of febrile seizures. *Pediatrics*. 2001;108(4). Available at: www.pediatrics.org/cgi/content/full/108/4/e63
3. Ekstrand JJ, Herbener A, Rawlings J, et al. Heightened neurologic complications in children with pandemic H1N1 influenza. *Ann Neurol*. 2010;68(5):762–766
4. Ekstrand JJ. Neurologic complications of influenza. *Semin Pediatr Neurol*. 2012;19(3):96–100
5. Farooq O, Faden HS, Cohen ME, et al. Neurologic complications of 2009 influenza-a H1N1 infection in children. *J Child Neurol*. 2012;27(4):431–438
6. Kwon S, Kim S, Cho MH, Seo H. Neurologic complications and outcomes of pandemic (H1N1) 2009 in Korean children. *J Korean Med Sci*. 2012;27(4):402–407
7. Landau YE, Grisaru-Soen G, Reif S, Fattal-Valevski A. Pediatric neurologic complications associated with influenza A H1N1. *Pediatr Neurol*. 2011;44(1):47–51
8. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. *J Pediatr*. 2007;150(3):306–310
9. Surana P, Tang S, McDougall M, Tong CY, Menson E, Lim M. Neurological complications of pandemic influenza A H1N1 2009 infection: European case series and review. *Eur J Pediatr*. 2011;170(8):1007–1015
10. Harder KM, Mølbak K, Glismann S, Christiansen AH. Influenza-associated illness is an important contributor to febrile convulsions in Danish children. *J Infect*. 2012;64(5):520–524
11. Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. *BMJ Open*. 2011;1(1):e000016
12. Blyth CC, Currie AJ, Wiertsema SP, et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. *Vaccine*. 2011;29(32):5107–5113
13. Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. *Vaccine*. 2012;30(11):2020–2023
14. Duffy J, Weintraub E, Hambidge SJ, et al; Vaccine Safety Datalink. Febrile seizure risk after vaccination in children 6 to 23 months. *Pediatrics*. 2016;138(1):e20160320
15. Vezzani A, Fujinami RS, White HS, et al. Infections, inflammation and epilepsy. *Acta Neuropathol*. 2016;131(2):211–234
16. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. *Nat Rev Neurol*. 2011;7(1):31–40
17. Legido A, Katsetos CD. Experimental studies in epilepsy: immunologic and inflammatory mechanisms. *Semin Pediatr Neurol*. 2014;21(3):197–206
18. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia*. 2014;55(4):475–482
19. Cowan LD. The epidemiology of the epilepsies in children. *Ment Retard Dev Disabil Res Rev*. 2002;8(3):171–181
20. Kim H, Byun SH, Kim JS, et al. Clinical and EEG risk factors for subsequent epilepsy in patients with complex febrile seizures. *Epilepsy Res*. 2013;105(1–2):158–163
21. Neligan A, Bell GS, Giavasi C, et al. Long-term risk of developing epilepsy after febrile seizures: a prospective cohort study. *Neurology*. 2012;78(15):1166–1170
22. Pavlidou E, Panteliadis C. Prognostic factors for subsequent epilepsy in children with febrile seizures. *Epilepsia*. 2013;54(12):2101–2107
23. Vestergaard M, Pedersen CB, Sidenius P, Olsen J, Christensen J. The long-term risk of epilepsy after febrile seizures in susceptible subgroups. *Am J Epidemiol*. 2007;165(8):911–918
24. Lee SH, Byeon JH, Kim GH, Eun BL, Eun SH. Epilepsy in children with a history of febrile seizures. *Korean J Pediatr*. 2016;59(2):74–79
25. MacDonald BK, Johnson AL, Sander JW, Shorvon SD. Febrile convulsions in 220 children—neurological sequelae at 12 years follow-up. *Eur Neurol*. 1999;41(4):179–186
26. Verity CM, Golding J. Risk of epilepsy after febrile convulsions: a national cohort study. *BMJ*. 1991;303(6814):1373–1376
27. Wilson JC, Toovey S, Jick SS, Meier CR. Previously diagnosed influenza infections and the risk of developing epilepsy. *Epidemiol Infect*. 2015;143(11):2408–2415
28. Ruf BR, Knuf M. The burden of seasonal and pandemic influenza in infants and children. *Eur J Pediatr*. 2014;173(3):265–276
29. Ghaderi S, Størdal K, Gunnes N, Bakken IJ, Magnus P, Håberg SE. Encephalitis after influenza and vaccination: a nationwide population-based registry study from Norway. *Int J Epidemiol*. 2017;46(5):1618–1626
30. Arnheim-Dahlström L, Hällgren J, Weibull CE, Sparén P. Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. *BMJ*. 2012;345:e7594
31. Scheffer IE. Vaccination triggers, rather than causes, seizures. *Epilepsy Curr*. 2015;15(6):335–337
32. Verbeek NE, Jansen FE, Vermeer-de Bondt PE, et al. Etiologies for seizures around the time of vaccination. *Pediatrics*. 2014;134(4):658–666
33. Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. *Vaccine*. 2016;34(6):714–722
34. Stowe J, Andrews N, Bryan P, Seabroke S, Miller E. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study. *Vaccine*. 2011;29(51):9467–9472

35. Barlow WE, Davis RL, Glasser JW, et al; Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. *N Engl J Med*. 2001;345(9):656–661

36. Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. *JAMA*. 2012;307(8):823–831

37. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. *Lancet Neurol*. 2014;13(6):600–613

38. Trogstad L, Bakken IJ, Gunnes N, et al. Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic. *Vaccine*. 2017;35(15):1879–1885

39. Duffy J, Weintraub E, Vellozzi C, DeStefano F; Vaccine Safety Datalink. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States. *Neurology*. 2014;83(20):1823–1830

40. Ringard Å, Sagan A, Sperre Saunes I, Lindahl AK. Norway: health system review. *Health Syst Transit*. 2013;15(8):1–162

41. The Norwegian Tax Administration. The national registry of Norway. 2016. Available at: www.skatteetaten.no/en/Person/National-Registry/This-is-the-National-Registry/. Accessed January 13, 2018

42. Bakken IJ, Surén P, Håberg SE, Cappelen I, Stoltenberg C. The Norwegian patient register—an important source for research [in Norwegian]. *Tidsskr Nor Laegeforen*. 2014;134(1):12–13

43. Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B. The Norwegian immunisation register–SYSVAK. *Euro Surveill*. 2012;17(16):20147

44. The Norwegian Directorate of Health. The Norwegian health economics administration. Available at: https://helfo.no/english/about-helfo. Accessed January 18, 2018

45. Håberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. *N Engl J Med*. 2013;368(4):333–340

46. Aaberg KM, Gunnes N, Bakken IJ, et al. Incidence and prevalence of childhood epilepsy: a nationwide cohort study. *Pediatrics*. 2017;139(5):e20163908

47. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. *Stat Med*. 2006;25(10):1768–1797

48. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. *Am J Epidemiol*. 1991;133(2):144–153

49. Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of epilepsy: a systematic review and meta-analysis. *Neurology*. 2011;77(10):1005–1012

50. Health Atlas (SKDE). Outpatient specialist care for epilepsy in children 0-16 years of age [in Norwegian]. 2017. Available at: www.helseatlas.no/sites/default/files/http-/www.helseatlas.no/getfile.php/SKDE-INTER/Helseatlas/pediatri_epilepsi_poli.pdf. Accessed May 29, 2017

51. Fukumoto Y, Okumura A, Hayakawa F, et al. Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications. *Brain Dev*. 2007;29(7):425–430

52. Cusick MF, Libbey JE, Patel DC, Doty DJ, Fujinami RS. Infiltrating macrophages are key to the development of seizures following virus infection. *J Virol*. 2013;87(3):1849–1860

53. Chung B, Wong V. Relationship between five common viruses and febrile seizure in children. *Arch Dis Child*. 2007;92(7):589–593

54. Kwong KL, Lam SY, Que TL, Wong SN. Influenza A and febrile seizures in childhood. *Pediatr Neurol*. 2006;35(6):395–399

55. Li-Kim-Moy J, Yin JK, Rashid H, et al. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children [published correction appears in *Euro Surveill*. 2015;20(25):21164]. *Euro Surveill*. 2015;20(24):21159

56. Millichap JG, Millichap JJ. Role of viral infections in the etiology of febrile seizures. *Pediatr Neurol*. 2006;35(3):165–172

57. Berg AT. Febrile seizures and epilepsy: the contributions of epidemiology. *Paediatr Perinat Epidemiol*. 1992;6(2):145–152

58. Cross JH. Fever and fever-related epilepsies. *Epilepsia*. 2012;53 (suppl 4):3–8

59. Seinfeld SA, Pellock JM, Kjeldsen MJ, Nakken KO, Corey LA. Epilepsy after febrile seizures: twins suggest genetic influence. *Pediatr Neurol*. 2016;55:14–16

60. Annegers JF, Hauser WA, Elveback LR, Kurland LT. The risk of epilepsy following febrile convulsions. *Neurology*. 1979;29(3):297–303

61. Nelson KB, Ellenberg JH. Predictors of epilepsy in children who have experienced febrile seizures. *N Engl J Med*. 1976;295(19):1029–1033

62. Pavlidou E, Hagel C, Panteliadis C. Febrile seizures: recent developments and unanswered questions. *Childs Nerv Syst*. 2013;29(11):2011–2017

63. Sadleir LG, Scheffer IE. Febrile seizures. *BMJ*. 2007;334(7588):307–311

64. Patel N, Ram D, Swiderska N, Mewasingh LD, Newton RW, Offringa M. Febrile seizures. *BMJ*. 2015;351:h4240

65. Salmon DA, Proschan M, Forshee R, et al; H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. *Lancet*. 2013;381(9876):1461–1468

Epilepsy in Children After Pandemic Influenza Vaccination

Siri E. Håberg, Kari M. Aaberg, Pål Surén, Lill Trogstad, Sara Ghaderi, Camilla Stoltenberg, Per Magnus and Inger Johanne Bakken

Pediatrics 2018;141;
DOI: 10.1542/peds.2017-0752 originally published online February 15, 2018;

PEDIATRICS®
OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Epilepsy in Children After Pandemic Influenza Vaccination

Siri E. Håberg, Kari M. Aaberg, Pål Surén, Lill Trogstad, Sara Ghaderi, Camilla Stoltenberg, Per Magnus and Inger Johanne Bakken

Pediatrics 2018;141;
DOI: 10.1542/peds.2017-0752 originally published online February 15, 2018;